The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

NCT05312151 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2025-06-13

Study results available
· View outcomes & findings →

Summary

The Safety and Tolerability of COMP360 in Participants with Post-traumatic Stress Disorder

Conditions

  • Post Traumatic Stress Disorder

Interventions

DRUG

Psilocybin

Open label

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-10
Primary Completion
2024-02-12
Completion
2024-02-12
FDA Drug
Yes

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05312151 on ClinicalTrials.gov